For the year ending 2025-12-31, BOLD had -$8,719K decrease in cash & cash equivalents over the period. -$47,207K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -58,197 |
| Stock-based compensation | 6,125 |
| Depreciation and amortization | 1,251 |
| Accretion of investments, net | 2,590 |
| Non-cash lease expense | 3,288 |
| Prepaid expenses and other assets | -332 |
| Accounts payable and accrued liabilities | 1,634 |
| Operating lease liabilities | 1,496 |
| Net cash used in operating activities | -46,661 |
| Purchases of investments | 174,897 |
| Maturities of investments | 213,244 |
| Purchases of property and equipment | 546 |
| Net cash provided by (used in) investing activities | 37,801 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 141 |
| Net cash provided by financing activities | 141 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | -8,719 |
| Cash, cash equivalents, and restricted cash at beginning of year | 27,147 |
| Cash, cash equivalents, and restricted cash at end of year | 18,428 |
Boundless Bio, Inc. (BOLD)
Boundless Bio, Inc. (BOLD)